You are adding an alert for:
TLR2 bridges oxidative damage and complement-associated pathology and is a therapeutic target for age-related macular degeneration.
You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
The alert will be sent to: